179 related articles for article (PubMed ID: 24969973)
1. Expression of p53, D2-40 and α-smooth muscle actin in different histological subtypes of facial basal cell carcinoma.
Mercut R; Ciurea ME; Mărgăritescu C; Popescu SM; Crăitoiu MM; Cotoi OS; Voinescu DC
Rom J Morphol Embryol; 2014; 55(2):263-72. PubMed ID: 24969973
[TBL] [Abstract][Full Text] [Related]
2. Expression of CXCR4, MMP-13 and β-catenin in different histological subtypes of facial basal cell carcinoma.
Ciurea ME; Cernea D; Georgescu CC; Cotoi OS; Pătraşcu V; Pârvănescu H; Popa D; Pârvănescu V; Ciurea RN; Mercuţ R
Rom J Morphol Embryol; 2013; 54(4):939-51. PubMed ID: 24398989
[TBL] [Abstract][Full Text] [Related]
3. Superficial radiotherapy for patients with basal cell carcinoma: recurrence rates, histologic subtypes, and expression of p53 and Bcl-2.
Zagrodnik B; Kempf W; Seifert B; Müller B; Burg G; Urosevic M; Dummer R
Cancer; 2003 Dec; 98(12):2708-14. PubMed ID: 14669293
[TBL] [Abstract][Full Text] [Related]
4. A correlation of alpha-smooth muscle actin and invasion in micronodular basal cell carcinoma.
Christian MM; Moy RL; Wagner RF; Yen-Moore A
Dermatol Surg; 2001 May; 27(5):441-5. PubMed ID: 11359490
[TBL] [Abstract][Full Text] [Related]
5. Presence of ulceration, but not high risk zone location, correlates with unfavorable histopathological subtype in facial basal cell carcinoma.
Yalcin O; Sezer E; Kabukcuoglu F; Kilic AI; Sari AG; Cerman AA; Altunay IK
Int J Clin Exp Pathol; 2015; 8(11):15448-53. PubMed ID: 26823913
[TBL] [Abstract][Full Text] [Related]
6. Expression of p16 Protein in Cutaneous Basal Cell Carcinoma: Still far from Being Clearly Understood.
Bartoš V
Acta Dermatovenerol Croat; 2020 Jul; 28(1):43-44. PubMed ID: 32650852
[TBL] [Abstract][Full Text] [Related]
7. Expression of p53 in aggressive and non-aggressive histologic variants of basal cell carcinoma.
Ansarin H; Daliri M; Soltani-Arabshahi R
Eur J Dermatol; 2006; 16(5):543-7. PubMed ID: 17101476
[TBL] [Abstract][Full Text] [Related]
8. Micronodular basal cell carcinoma: a distinct subtype? Relationship with nodular and infiltrative basal cell carcinomas.
Betti R; Menni S; Radaelli G; Bombonato C; Crosti C
J Dermatol; 2010 Jul; 37(7):611-6. PubMed ID: 20629826
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical expression of p53, Ki67, α-SMA, CD44 and CD31 in different histological subtypes of basal cell carcinoma.
Cojocaru A; Bîrjovanu C; Ciurea AM; Niculescu D; Orzan OA; Ion A; Alexandru DO; Pirici I; Vîlcea EJ; Marinescu EA; Ciurea ME
Rom J Morphol Embryol; 2022; 63(2):383-393. PubMed ID: 36374143
[TBL] [Abstract][Full Text] [Related]
10. Stromal expression of actin is a marker of aggressiveness in basal cell carcinoma.
Adegboyega PA; Rodriguez S; McLarty J
Hum Pathol; 2010 Aug; 41(8):1128-37. PubMed ID: 20381122
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical nuclear staining for p53, PCNA, and Ki-67 in different histologic variants of basal cell carcinoma.
Barrett TL; Smith KJ; Hodge JJ; Butler R; Hall FW; Skelton HG
J Am Acad Dermatol; 1997 Sep; 37(3 Pt 1):430-7. PubMed ID: 9308559
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical Expression of Calponin in Cutaneous Basal Cell Carcinoma.
Bartoš V; Kullová M
Acta Dermatovenerol Croat; 2015; 23(4):254-9. PubMed ID: 26724876
[TBL] [Abstract][Full Text] [Related]
13. Recurrence rates of aggressive histologic types of basal cell carcinoma after treatment with electrodesiccation and curettage alone.
Blixt E; Nelsen D; Stratman E
Dermatol Surg; 2013 May; 39(5):719-25. PubMed ID: 23379543
[TBL] [Abstract][Full Text] [Related]
14. Interaction between bcl-2 and P53 in neoplastic progression of basal cell carcinoma of the head and neck.
Staibano S; Lo Muzio L; Pannone G; Scalvenzi M; Salvatore G; Errico ME; Fanali S; De Rosa G; Piattelli A
Anticancer Res; 2001; 21(6A):3757-64. PubMed ID: 11911244
[TBL] [Abstract][Full Text] [Related]
15. High discordance between punch biopsy and excision in establishing basal cell carcinoma subtype: analysis of 500 cases.
Wolberink EA; Pasch MC; Zeiler M; van Erp PE; Gerritsen MJ
J Eur Acad Dermatol Venereol; 2013 Aug; 27(8):985-9. PubMed ID: 22759209
[TBL] [Abstract][Full Text] [Related]
16. bcl-2 protein expression in aggressive and non-aggressive basal cell carcinomas.
Ramdial PK; Madaree A; Reddy R; Chetty R
J Cutan Pathol; 2000 Jul; 27(6):283-91. PubMed ID: 10885404
[TBL] [Abstract][Full Text] [Related]
17. Immunoreactivity for alpha-smooth muscle actin characterizes a potentially aggressive subgroup of little basal cell carcinomas.
Pilloni L; Bianco P; Manieli C; Senes G; Coni P; Atzori L; Aste N; Faa G
Eur J Histochem; 2009; 53(2):113-6. PubMed ID: 19683985
[TBL] [Abstract][Full Text] [Related]
18. Agreement between histological subtype on punch biopsy and surgical excision in primary basal cell carcinoma.
Roozeboom MH; Mosterd K; Winnepenninckx VJ; Nelemans PJ; Kelleners-Smeets NW
J Eur Acad Dermatol Venereol; 2013 Jul; 27(7):894-8. PubMed ID: 22691131
[TBL] [Abstract][Full Text] [Related]
19. Basal cell carcinoma of the skin with mixed histomorphology: a comparative study.
Bartoš V; Kullová M
Cesk Patol; 2016; 52(4):222-226. PubMed ID: 27869450
[TBL] [Abstract][Full Text] [Related]
20. Immunoexpression of p53 and COX-2 in basal cell carcinoma.
Enache AO; Stepan AE; Mărgăritescu C; Pătraşcu V; Ciurea RN; Simionescu CE; Camen A
Rom J Morphol Embryol; 2018; 59(4):1115-1120. PubMed ID: 30845292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
